Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review (Q37698748)

22 August 2017

1 reference

title

Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review (English)

1 reference

Maarten Franciscus Schim van der Loeff

22 August 2017

0 references

anti-retroviral agent

0 references

0 references

0 references

1 reference

2

object named as

Maarten F Schim van der Loeff

1 reference

22 August 2017

Roos E Barth

1

1 reference

22 August 2017

Rob Schuurman

3

1 reference

22 August 2017

Andy I M Hoepelman

4

1 reference

22 August 2017

Annemarie M J Wensing

5

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Lancet Infectious Diseases

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

155-166

1 reference

Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Low Levels of Antiretroviral‐Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second‐Line

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Antiretroviral drug resistance and routine therapy, Cameroon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Evaluation of a workplace HIV treatment programme in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Adherence is not a barrier to successful antiretroviral therapy in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

Virologic, Immunologic, and Clinical Response to Highly Active Antiretroviral Therapy: the Gender Issue Revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970328-7

7 January 2021

10.1016/S1473-3099(09)70328-7

Identifiers

DOI

1 reference

22 August 2017

1 reference